CD&R and McKesson agree to buy Option Care Health for $5.8 billion
Clayton, Dubilier & Rice and McKesson agreed on October 6, 2026 to purchase Option Care Health in an all-cash transaction. Shareholders would receive $32.05 a share, and the deal values the home-infusion provider at about $5.8 billion including debt. CD&R is set to control the privately held company with 51%, while McKesson would hold 49% after closing.
Why it matters
The cash offer sets a fixed value for Option Care shareholders, with the remaining issue being whether the transaction receives the required votes and clearances. McKesson said Option Care's nationwide operations support its effort to broaden access to complex specialty treatments outside higher-cost settings.
Key facts
- 1CD&R and McKesson signed a definitive agreement to acquire Option Care Health on 6 October 2026. financial-news.co.uk
- 2The buyers offered $32.05 a share, implying an enterprise value of about $5.8 billion including debt. ibtimes.com.au
- 3CD&R will own 51%, while McKesson will hold 49% and invest about $1.4 billion. finance.yahoo.com
- 4McKesson has a contractual framework to purchase CD&R's stake later, subject to conditions and regulatory clearance. finance.yahoo.com
- 5The companies target a closing in the first half of 2027, contingent on shareholder consent and regulatory clearances. finance.yahoo.com
- 6Option Care would leave Nasdaq and become privately held once the deal is completed. finance.yahoo.com
Open questions
- One report says the transaction is expected to close in 2024, while other reports give a first-half 2027 target.
Summary written by AlphAI from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.